Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > It’s over.

<< Previous

Bullboard Posts

Next >>

Comment by Rarbar99on Aug 17, 2021 5:37pm

225 Views

Post# 33721103

RE:RE:It’s over.

It's not speculation. If the company knew this was all fudd and an overreaction, they would be eating up this dip along with many institutional buyers. But they're not. No one is. They know this is not an overreaction and they know it's going to go lower. It's really that simple.

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – Nov. 6, 2024